

Junod, Rebecca

From: Sean McCabe <Sean.McCabe@btgplc.com>
Sent: Wednesday, January 17, 2018 10:17 AM
To: Elliott, Robin
Subject: [External_Sender] Dr. Posteraro AU training for TheraSphere

J-2

06-00854-03
03001246

Hello Robin,

As we discussed over the phone last week, the medical science liaisons at BTG are committed to providing comprehensive training to prospective TheraSphere Authorized Users. We strictly adhere to the requirements outlined by the NRC Y90 microsphere brachytherapy guidelines. As such, it is our practice to provide a letter to the AU in training and the site's RSO once the physician has completed the NRC A thru G Safe Handling practices and three kit setups with *in-vitro* simulations. In accordance to Pathway 2, a second and final letter is also provided to the AU in training and the site's RSO once the physician has completed three patient administrations in which >90% of intended dose was delivered to the target tissue. The dates of these cases are listed in the letter along with the dates of previously completed training.

I hope this clarifies our process as it relates to Dr. Posteraro's training and his training completion letter that was provided by BTG. Please let me know if I can be of any further assistance.

Best regards,
Sean

Sean McCabe
Medical Science Liaison

Biocompatibles Inc., a BTG International group company
Five Tower Bridge, Suite 810, 300 Barr Harbor Drive
West Conshohocken, PA, 19428-2998 USA
T: +1 610 278 1660 | M: +1 518 812 9748 | F: +1 610 943 6018
sean.mccabe@btgplc.com
www.btgplc.com



 Please consider the environment before printing this email.

The above company is a subsidiary of BTG plc, a company registered in England and Wales (Registered Number 2670500) which has its registered office at 5 Fleet Place, London EC4M 7RD, UK.

BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in the US, EU and certain other territories, and are trademarks of BTG International Ltd elsewhere.